Smoldering Myeloma Endpoint Questions Carry J&J’s Darzalex Faspro To US FDA AdComm

 
• By Bridget Silverman
  
US FDA questions about trial endpoints could dampen J&J's hopes for the first smoldering myeloma indication. (Shutterstock)

More from US Advisory Committees

More from Product Reviews